Price to sales forward of Harmony Biosciences Holdings, Inc. – NASDAQ:HRMY
This article displays the "Price to sales forward" metric for Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) on the TradingView platform. The content primarily shows navigation elements and general information about TradingView and FactSet, with the specific financial data point "Price to sales forward" present but without a numerical value or further details.
HRMY - Harmony Biosciences Holdings Inc Latest SEC Filings
This article provides the latest SEC filing information and detailed financial performance data for Harmony Biosciences Holdings Inc (HRMY). It covers key metrics such as market capitalization, income, sales, P/E ratio, EPS, insider ownership, institutional ownership, and various stock performance indicators. The data reflects the company's financial health, growth, and market activity as of July 6, 2026.
Harmony Biosciences holds steady as investors await the next catalyst.
Harmony Biosciences (HRMY) is a Nasdaq-listed biopharmaceutical company specializing in rare-disease treatments, primarily a wakefulness therapy for narcolepsy. The stock is currently trading without a new company-specific catalyst, with investor focus on its existing commercial franchise, execution, and pipeline progress. The company's profile makes it sensitive to regulatory updates, commercial momentum, and pipeline readouts.
25,000-share option exercise; affiliate sales reported — HRMY
A Form 144 notice filed by Morgan Stanley Smith Barney LLC for Harmony Biosciences Holdings, Inc. (HRMY) reports a planned 25,000-share option exercise on July 2, 2026, to be settled in cash. The filing also details multiple recent sales by Sandip Kapadia during June-July 2026, including a 50,000-share transaction on June 30, 2026. Experts characterize these as routine affiliate disclosures, indicating a neutral impact on the stock.
Form 144 HARMONY BIOSCIENCES HOLDINGS For: 30 June By Investing.com
This article announces the filing of Form 144 by HARMONY BIOSCIENCES HOLDINGS for the period ending June 30. It is a brief announcement from Investing.com, providing basic information about the filing.
Form 144 HARMONY BIOSCIENCES HOLDINGS For: 30 June By Investing.com
This article from Investing.com reports on the filing of Form 144 for Harmony Biosciences Holdings (HRMY) for the period ending June 30. The brief entry indicates this financial filing is available, presumably providing details on insider sales or purchases of restricted securities, a routine disclosure for publicly traded companies.
Form 144 HARMONY BIOSCIENCES HOLDINGS For: 30 June By Investing.com
This article announces the Form 144 filing for HARMONY BIOSCIENCES HOLDINGS for June 30th. It is a brief announcement from Investing.com, providing basic information about the filing and the company's stock performance. The article also includes various market data and other news.
Sandip Kapadia reports sale activity (HRMY) via Form 144 totaling 50,000
Sandip Kapadia has filed a Form 144 indicating an intention to sell up to 50,000 shares of Harmony Biosciences Holdings, Inc. (HRMY) common stock. The filing details that these shares are part of an Exercise of Options Under a Registered Plan with cash settlement, handled by Morgan Stanley Smith Barney LLC. The document also discloses several previous sales by Kapadia in May and June 2026, including specific share counts and gross proceeds for each transaction.
Is Harmony Biosciences (HRMY) Quietly Recasting Its Single-Drug Story Into a Broader Neuroscience Platform?
Harmony Biosciences (HRMY) is working to diversify its portfolio beyond its primary sleep drug, Wakix, by developing new indications and formulations for pitolisant and advancing other neuroscience assets. This strategy aims to reduce reliance on a single product and build a broader neuroscience franchise. The company's expansion efforts could challenge more bearish analyst views and potentially unlock significant upside for investors, as forecasts project substantial revenue and earnings growth by 2028.
HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase
Harmony Biosciences (HRMY) is evolving beyond its core Wakix revenue by investing in a broader neuroscience strategy. The company is advancing pitolisant for new indications and developing new formulations, alongside entering the orexin and rare epilepsy markets. While these initiatives offer credible growth trends, the stock's performance will depend on the successful execution and commercialization of these pipeline assets amidst increasing competition.
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?
Harmony Biosciences Holdings, Inc. (HRMY) presents a balanced investment case with a seemingly cheap valuation, strong operating figures centered around its drug Wakix, and a funded pipeline. However, recent earnings misses and a reliance on a single product introduce caution, balancing the potential for future growth from its pipeline against present market access challenges and increased R&D spending. The stock currently holds a Zacks Rank #3 (Hold), suggesting a neutral near-term outlook despite favorable valuation and growth scores.
Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline
Harmony Biosciences is leveraging its successful narcolepsy drug, Wakix, to expand into a broader neuroscience platform. While Wakix continues to be the primary revenue driver with strong growth, the company is developing new formulations of pitolisant and advancing a broader pipeline of CNS assets to reduce its dependence on a single product. Despite promising pipeline developments, risks include revenue concentration, increasing market competition, and potential generic entry for Wakix, leading to a "Hold" rating from Zacks Investment Research.
Harmony Biosciences Holdings Inc (HRMY) Stock Forecast, Price Targets and Analysts Predictions
The article provides a GuruFocus overview for Harmony Biosciences Holdings Inc (HRMY), including its current stock price, market capitalization, P/E and P/B ratios, and GF Score. It also mentions features available to subscribers, such as 12-month price targets and analyst ratings, indicating the platform's focus on detailed financial analysis and forecast data for investors.
Form 144 HARMONY BIOSCIENCES HOLDINGS For: 26 June By Investing.com
This article provides details about a Form 144 filing for Harmony Biosciences Holdings (HRMY) made on June 26th. It mentions the stock's performance and includes general financial market data and popular news articles unrelated to the specific filing.
The Technical Signals Behind (HRMY) That Institutions Follow
This article analyzes Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) using AI models to provide technical signals and institutional trading strategies. It highlights a strong near and mid-term sentiment, a mid-channel oscillation pattern, and identifies specific entry, target, and stop-loss zones for long, breakout, and short positions. The analysis offers a detailed multi-timeframe signal breakdown for institutional-grade insights.
HRMY affiliate gives notice to sell 45,594 shares (NASDAQ: HRMY)
Harmony Biosciences (NASDAQ: HRMY) has an affiliate, Sandip Kapadia, who filed a Form 144 notice to sell 45,594 shares. This proposed sale is due to the exercise of options under a registered plan, with a listed cash proceeds amount of $1,606,823.75. The filing also details several recent sales by Sandip Kapadia between May and June 2026.
Harmony Biosciences Holdings, Inc. Actuals & Estimates (SWB:60H)
This article provides an overview of Harmony Biosciences Holdings, Inc. (SWB:60H) financials, including actuals and analyst estimates. It covers historical earnings and revenue, future forecasts, employee count, and EBITDA. Key information includes the upcoming earnings report date on August 11, 2026, and a detailed look at past earnings surprises and revenue figures.
Harmony Biosciences Holdings, Inc. Actuals & Estimates (NASDAQ:HRMY)
This article provides an overview of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), including its current stock price, market capitalization, financial performance, and analyst forecasts. It highlights the company's financial actuals and estimates for income, balance sheet, and cash flow, alongside key metrics like earnings per share and revenue. The article also touches upon HRMY's stock volatility, historical highs and lows, and upcoming earnings report.
HRMY Forecast — Price Target — Prediction for 2027
This article provides an in-depth stock analysis for Harmony Biosciences Holdings, Inc. (HRMY), including its current price, analyst price targets, and historical performance. It also details financial metrics like EPS, revenue, net income, and market capitalization, along with upcoming earnings dates. The analysis includes discussions on volatility, analyst ratings, and dividend policy.
H.C. Wainwright reiterates Harmony Biosciences stock rating at buy By Investing.com
H.C. Wainwright has reiterated its Buy rating and $55.00 price target on Harmony Biosciences (NASDAQ: HRMY), despite the company reporting an earnings miss in Q1 2026. The firm highlighted data presented at SLEEP 2026 supporting Harmony's pitolisant lifecycle strategy, including high-dose and gastro-resistant formulations. Harmony Biosciences' stock is considered undervalued by InvestingPro, with a fair value of $47.96, and the company maintains a robust financial position.
Sandip Kapadia (HRMY) files Rule 144 notice, Morgan Stanley as broker
Sandip Kapadia has submitted a Form 144 to notify a proposed disposition of Harmony Biosciences Holdings, Inc. (HRMY) Common Stock, with Morgan Stanley Smith Barney LLC listed as the broker. The filing details recent dispositions including 45,481 shares on May 8, 2026, and several other transactions in June 2026. This filing is a compliance document for proposed sales under Rule 144, not a confirmation of completed sales, and indicates the potential future resale of restricted or control securities.
H.C. Wainwright reiterates Harmony Biosciences stock rating at buy
H.C. Wainwright has reiterated a Buy rating and a $55.00 price target for Harmony Biosciences Holdings Inc. (NASDAQ: HRMY). The firm's analysis, supported by presentations at SLEEP 2026, highlights the potential of Harmony's pitolisant lifecycle strategy, including high-dose and gastro-resistant formulations of pitolisant for narcolepsy and idiopathic hypersomnia. Despite recent financial challenges, including an earnings miss in Q1 2026 due to licensing expenses, the company's financial health remains strong, and its stock is considered undervalued by InvestingPro analysis.
Harmony Biosciences Stock - Analyst consensus and technical backdrop
Harmony Biosciences (HRMY) currently holds a "Hold" consensus from Wall Street analysts, trading in a defined range on Nasdaq. The stock closed at $33.28 on June 18, 2026, with analysts showing a cautious balance between buy, hold, and sell ratings. The company's primary revenue source is its narcolepsy treatment, WAKIX, and it continues to invest in clinical development to expand its product offerings.
Harmony Biosciences Holdings Inc (HRMY) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Harmony Biosciences Holdings Inc (HRMY), noting its current valuation score of 8.08 and its ranking in the Pharmaceuticals industry. It highlights the company's current P/E ratio of 13.36, which is significantly below its recent high and above its recent low. The article also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Harmony Biosciences Holdings Inc (HRMY) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Harmony Biosciences Holdings Inc's (HRMY) shareholder structure, listing major shareholders and their proportions, as well as categorizing shareholder types. It also presents institutional shareholding data over several quarters, including the number of institutions, shares held, and changes in proportion. Additionally, the article highlights recent shareholder activity and related ETF holdings for HRMY.
Harmony Biosciences Holdings Inc
The article provides a revenue breakdown for Harmony Biosciences Holdings Inc (HRMY), including market capitalization, P/E ratio, and stock performance. It notes that relevant data for business segments and regional revenue contribution have not yet been disclosed by the company, though it does show a United States revenue of $868.45M. The article also provides general financial data and company overview.
Precision Trading with Harmony Biosciences Holdings Inc. (HRMY) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Harmony Biosciences Holdings Inc. (HRMY) using AI models to identify trading strategies across different risk profiles and holding periods. It highlights a strong near and mid-term sentiment, a significant risk-reward short setup, and offers specific entry, target, and stop-loss zones for position, momentum breakout, and risk hedging strategies. The analysis is based on multi-timeframe signal strengths and identifies key support and resistance levels for HRMY.
Precision Trading with Harmony Biosciences Holdings Inc. (HRMY) Risk Zones
This article provides a precision trading analysis for Harmony Biosciences Holdings Inc. (HRMY), highlighting a mid-channel oscillation pattern and an exceptional short setup with a 45.4:1 risk-reward ratio. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis and support/resistance levels. The analysis emphasizes strong near-term and mid-term positive sentiment, suggesting a potential extension to the long term.
Harmony Biosciences (HRMY) Stock Valuation After New Pitolisant Data And Reaffirmed Guidance
Harmony Biosciences (HRMY) is gaining attention after announcing new Pitolisant data presentations and reaffirming its guidance, leading to a 16.75% share price return in the last 30 days. Despite this short-term momentum, the stock has a modest 5.61% one-year return and a 10.2% five-year return. Simply Wall St's analysis suggests HRMY is significantly undervalued, with a fair value of $47.30 per share against a market price of $35.20, driven by an expanding addressable market for its sleep disorder and rare neurodevelopmental treatments.
Six narcolepsy and hypersomnia studies from Harmony at SLEEP 2026
Harmony Biosciences (Nasdaq: HRMY) announced that six of its abstracts focusing on narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at the SLEEP 2026 annual meeting. These presentations include analyses of Pitolisant's effects on sleep patterns, results from Phase 1b and Phase 3 clinical trials for HBS-301 and Pitolisant, and patient experience studies. The findings reinforce Harmony Biosciences' commitment to developing innovative therapies for rare neurological diseases.
Is Harmony Biosciences Holdings, Inc. (HRMY) A Good Stock To Buy Now?
Harmony Biosciences Holdings, Inc. (HRMY) is presented as a compelling investment opportunity due to its undervaluation, strong performance of its flagship drug WAKIX, and promising growth pipeline. The company exhibits robust financial health with high gross margins and self-funding capacity. Analysts project significant upside potential, highlighting attractive risk-reward for investors.
HRMY (NASDAQ) affiliate: option exercise 27,960 shares; Kapadia sells 54,646
Harmony Biosciences Holdings, Inc. (HRMY) affiliate reported a Form 144 filing detailing the exercise of options for 27,960 shares and the sale of 54,646 common shares by Sandip Kapadia across several transactions in May and June 2026. The filing provides specific dates, share counts, and cash proceeds for each transaction, indicating routine administrative disclosures related to securities sales.
HRMY affiliate files Rule 144 sale notice (NASDAQ: HRMY) for option exercises
Harmony Biosciences Holdings, Inc. (HRMY) submitted a Rule 144 notice for proposed common stock sales related to option exercises on June 5, 2026. The filing indicates recent dispositions of 7,064 shares for $233,232.09 on June 4, 2026, and 45,481 shares for $1,433,056.28 on May 8, 2026. As of June 5, 2026, the company had 57,892,676 shares outstanding.
Sandip Kapadia files Form 144 proposing sale of 45,481 HRMY shares (HRMY)
Sandip Kapadia has filed a Form 144 indicating a proposed sale of 45,481 shares of Harmony Biosciences Holdings, Inc. (HRMY). The filing details a completed sale on May 8, 2026, for an aggregate amount of $1,433,056.28, and a planned transaction tied to an option exercise under a registered plan dated June 4, 2026. This notice is a regulatory compliance document for proposed insider sales.
Technical Reactions to HRMY Trends in Macro Strategies
This article from Stock Traders Daily provides a technical analysis of Harmony Biosciences Holdings Inc. (NASDAQ: HRMY), highlighting a strong near and mid-term sentiment that could extend to the long term. It identifies a mid-channel oscillation pattern and offers three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and key findings regarding potential gains and risk.
HRMY or ARGX: Which is the better value stock right now?
This article compares HRMY and ARGX to determine which is the better value stock. It likely analyzes various financial metrics and market positions of both companies to arrive at a conclusion. The content promises to provide insights for investors interested in these two particular stocks.
Harmony Biosciences to Participate in Upcoming Investor Conferences
Harmony Biosciences (Nasdaq: HRMY) announced its management team will attend two investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, and the Oppenheimer CNS & Neuro-Muscular Summit on June 10, 2026. Webcasts of the fireside chats will be available on the company's investor relations website. The company specializes in developing therapies for rare neurological diseases.
H.C. Wainwright reiterates Harmony Biosciences stock rating at buy
H.C. Wainwright maintained a Buy rating and a $55.00 price target for Harmony Biosciences (NASDAQ:HRMY) despite the company missing first-quarter 2026 revenue and GAAP EPS consensus estimates. The miss was primarily due to high licensing expenses, but Harmony Biosciences remains profitable with a strong gross profit margin and substantial cash reserves. The firm cited upcoming catalysts across pitolisant lifecycle management, orexin-2 receptor agonism, and rare epilepsy for its continued positive outlook.
HRMY SEC Filings - Harmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms
This page on StockTitan provides a comprehensive collection of SEC filings for Harmony Biosciences Holdings, Inc. (HRMY), including 10-K, 10-Q, 8-K forms, and insider trading reports. Each filing is accompanied by an AI-generated summary, impact score, and sentiment analysis. Recent filings discuss preliminary Q3 revenue, insider stock transactions, and clinical trial results.
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY). The firm also maintained a price target of $55.00 for the company. The full article content is only available to premium subscribers.
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Harmony Biosciences reported its Q1 financial results and reaffirmed its 2026 net revenue guidance of over $1 billion. The company also reinforced its strategic priorities for 2026. This announcement indicates the company's confidence in its future financial performance and strategic direction.
Harmony Revenue Rises as WAKIX Franchise Expands
Harmony Biosciences reported a 17% revenue increase for its narcolepsy drug WAKIX in the first quarter, reaching $215.4 million, and reaffirmed its full-year revenue guidance between $1 billion and $1.04 billion. The company is actively expanding its WAKIX franchise through patent litigation, new formulations like pitolisant GR and HD, and pipeline programs such as BP-205 and EPX-100, aiming for durability into the 2030s. Despite a decline in net income due to licensing expenses, Harmony secured FDA approval for a pediatric cataplexy indication for WAKIX and ended the quarter with $870.5 million in cash.
Harmony Biosciences (HRMY) director awarded 21,872 stock options at $30.76 strike price
Harmony Biosciences director Juan A. Sabater was granted 21,872 stock options with an exercise price of $30.76 per share, vesting on the earlier of May 14, 2027, or the next annual meeting, provided he continues service. These options expire on May 14, 2036. This transaction is a compensation award, not a market purchase or sale, and represents his direct holdings of derivative securities.
A beaten-down biotech just lost a meaningful backer — should you care?
Bridge City Capital, LLC, has fully divested its investment in Harmony Biosciences Holdings (NASDAQ:HRMY) during the first quarter of 2026, selling all 237,103 shares for an estimated $7.77 million. Harmony Biosciences, a healthcare company, focuses on developing treatments for rare neurological diseases and aims to address unmet medical needs in the U.S. market. This complete exit by a significant backer might raise questions about the implications for the biotech firm's future.
Harmony Biosciences (HRMY) director receives 21,872-share stock option grant
Harmony Biosciences director Linda M. Szyper was granted 21,872 stock options with an exercise price of $30.76 per share, expiring on May 14, 2036. This grant serves as compensation, not an open-market purchase, and vests fully on the earlier of May 14, 2027, or the next annual meeting, contingent on her continued service. Following this transaction, Szyper holds 21,872 derivative securities of Harmony Biosciences common stock.
Harmony Biosciences (HRMY) director Germano Geno J files initial insider Form 3
Harmony Biosciences Holdings, Inc. director Germano Geno J has filed an initial Form 3 with the SEC, which officially lists him as a reporting person for the company. This filing is a mandatory first insider ownership report for company officers, directors, and large shareholders. It establishes his reporting status but does not indicate any current share transactions or beneficial ownership.
Harmony Biosciences (HRMY) director granted 21,231 stock options
Harmony Biosciences Holdings, Inc. director Germano Geno J was granted 21,231 stock options as equity compensation. These options, with an exercise price of $30.76 per share and an expiration date of May 14, 2036, will vest in 36 equal monthly installments starting on June 14, 2026. This transaction is a compensation grant and not an open-market purchase or sale.
Harmony Biosciences director granted 21,872 options | HRMY Insider Trading
Harmony Biosciences director Philip Ron M was granted 21,872 stock options with an exercise price of $30.76 per share, expiring on May 14, 2036. The options will vest in full by May 14, 2027, or the date of the next annual meeting, contingent on his continued service. This transaction is a compensation-related award, not an open-market purchase or sale.
Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY)
Harmony Biosciences (HRMY) reported a dip in net income for Q1 2026, though net product revenue grew by 17%. The company is focused on WAKIX, having received FDA approval for pediatric cataplexy and actively pursuing patent protection into 2030, despite near-term earnings pressure. Investors should consider the company's reliance on WAKIX and ongoing patent litigation as key factors influencing its investment narrative.
Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY)
Harmony Biosciences (HRMY) experienced a dip in Q1 2026 net income, yet reported 17% net product revenue growth and secured FDA approval for a pediatric cataplexy indication for WAKIX. The company faces ongoing patent litigation for WAKIX, which is crucial for its revenue guidance, and investors are advised to consider the long-term implications of these legal disputes and potential generic competition. Despite an earnings miss, the investment narrative still largely hinges on WAKIX's performance and patent protection, with analysts predicting future revenue and earnings growth.
